Business Wire

CA-CYARA

5.4.2022 15:02:09 CEST | Business Wire | Press release

Share
Cyara Adds Leading Automated Chatbot Testing to Customer Experience Assurance Offerings with Acquisition of Botium

Cyara , provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today closed its acquisition of industry-leading automated chatbot testing company, Botium , which adds chatbot and conversational AI testing capabilities to its portfolio, further solidifying its position as the global leader in the CX testing and assurance market.

The chatbot market is rapidly growing, with a 22.5% compound annual growth rate (CAGR) projected between 2020 and 2027. The increased use of chatbots and natural language understanding (NLU) throughout the digital customer journey has created the need for solutions that can efficiently and effectively test and monitor the performance of chatbots and conversational AI. Botium provides solutions that solve this unique need to Cyara, bolstering the comprehensiveness of its automated CX assurance capabilities across digital channels and making it an ideal addition to Cyara’s existing portfolio of solutions that enable customers to assure their CX is flawless.

The acquisition is part of Cyara’s strategic plan for international growth and product innovation, fueled by its recent $350 million growth investment . Cyara’s mission is to deliver a complete CX assurance platform that will test customer journeys cohesively, regardless of channel or whether those journeys are delivered through a single platform or multiple best-of-breed solutions. More than 100 million chatbot tests have been executed on Botium Box and the company has a 92% recurring customer rate. Botium brings over 1,500 Botium Box customers, in addition to 185,000 open source users. Additionally, the acquisition expands Cyara’s existing international presence to Central Europe, with Botium’s offices in Austria.

“This acquisition is a major milestone in Cyara’s growth and it further enhances our ability to help companies assure their end-to-end customer experiences,” said Alok Kulkarni, CEO of Cyara. “We are so pleased to join forces with Botium to provide an easy way for enterprises to ensure their CX through an IVR, chatbot, agent-based phone, or some combination of voice and digital channels is flawless.

Botium, named in 2021 as a Gartner Cool Vendor in Conversational and Natural Language Technologies , brings deep expertise in chatbots, conversational AI and NLU to Cyara. Its skilled workforce will join Cyara’s digital CX assurance development team. Chatbots and conversational AI present unique challenges for testing and monitoring. Given all the possible permutations that could occur, manual testing is simply not possible. Botium’s automated chatbot testing improves the quality of the chatbot, ensuring it performs as expected, all while reducing the efforts of enterprise IT teams and shortening the time-to-market for chatbots. Its solution provides added value in every phase of the customers’ bot development lifecycle.

“We see Cyara as a natural fit since it is a forward-looking company that’s well-positioned to lead the digital CX assurance category,” said Christoph Börner, Co-founder and CEO of Botium. “The Botium team is made up of talented developers and engineers, and joining Cyara’s team will give us additional resources to expand our efforts in developing innovative solutions for testing chatbots and conversational AI, as well as reaching a wider global customer base.”

To learn more about Cyara’s CX assurance capabilities and the acquisition news, please visit: https://cyara.com/botium-box/ .

About Cyara’s Automated CX Assurance Platform

The Cyara Automated CX Assurance Platform is used by some of the world’s top brands to automate and accelerate testing of the CX they deliver, measure and optimize the quality of digital and voice channels, and then assure flawless omnichannel customer journeys from beginning to end. CX experts use Cyara’s cloud-based platform to define customer journeys that Cyara’s automated bots engage with by testing the network, applications, and even back-end data systems that power those journeys. Any issues that a customer may experience in how those journeys perform are identified so organizations can resolve them before they impact a customer.

About Cyara

As the world’s leading Automated CX Assurance platform provider, Cyara accelerates the delivery of flawless customer journeys across digital and voice channels while reducing the risk of customer-facing defects. Every day, the most recognizable brands in the world trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/Cyara

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye